Thanks to modern imaging and molecular characterization, neuroendocrine tumours can now be detected and classified in a much more targeted manner. New therapeutic procedures such as radioligand therapy and targeted drugs are increasingly enabling individualized treatment strategies.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- ENETS
- ENETS-certified center Inselspital Bern
- gastroenteropancreatic NET peptide receptor radionuclide therapy (PRRT)
- heterogeneous group of neoplasms
- Hormone-producing cells of the neuroendocrine system
- NET histopathological and immunohistochemical examinations
- NET localizations of the gynaecological tract
- NET precise morphological and molecular characterization
- NET somatostatin receptor expression
- NET Somatostatin receptor PET/CT
- NET Tumor Biology
- NET University Hospital Zurich
- Neuroendocrine tumors (NET)
- SeqEveRIV study
- SwissNET
You May Also Like
- HER2+ metastatic breast cancer
New therapeutic standards with SHR-A 1811
- Angina tonsillaris: clinical management
Conservative therapy or surgery?
- Dermocosmetic for mild to moderate acne
Effects of an anti-pimple cream: randomized split-face study
- Neuro-ophthalmology
Visual Snow Syndrome: From the mysterious disorder to effective treatment options
- Platelet and leukocyte abnormalities
Clonal or reactive causes?
- Gonarthrosis and coxarthrosis: update on conservative treatment
Pain relief, targeted movement and relief
- Idiopathic and progressive pulmonary fibrosis (IPF/PPF)
An instrument for clinical use
- Rosacea - multifaceted and multifactorial